Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07610278
PHASE2

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.

Official title: A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-06-03

Completion Date

2028-01-28

Last Updated

2026-05-27

Healthy Volunteers

No

Interventions

DRUG

QCZ484

QCZ484 once on Day 1

DRUG

Inclisiran

Inclisiran once on Day 1

DRUG

QCZ484 placebo

QCZ484 placebo once on Day 1

DRUG

Inclisiran placebo

Inclisiran placebo once on Day 1